Sera Prognostics, Inc.
SERA
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditionsā¦ read more
Healthcare
Diagnostics & Research
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.52
Price-6.67%
-$0.18
1Y
Price
Market Cap
$93.477m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-45923.5%
EBITDA Margin-47329.4%
Net Profit Margin-33847.1%
Free Cash Flow MarginRevenue
$108k
+40.3%
1y CAGR-6.8%
3y CAGR+51.6%
5y CAGREarnings
-$32.731m
+0.5%
1y CAGR+9.3%
3y CAGR+1.4%
5y CAGREPS
-$0.85
+14.1%
1y CAGR+15.9%
3y CAGR+6.6%
5y CAGRBook Value
$88.226m
$111.828m
Assets$23.602m
Liabilities$351k
DebtDebt to Assets
0.3%
-
Debt to EBITDAFree Cash Flow
-$26.947m
-89.2%
1y CAGR-6.2%
3y CAGR-6.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company